ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 0616

Disparities in Health-Related Quality of Life Among Patients with Systemic Lupus Erythematosus

Victoria Delk1, Dulaney Wilson2, Gary Gilkeson2, Jim Oates2 and Diane Kamen2, 1Medical University of South Carolina, North Charleston, SC, 2Medical University of South Carolina, Charleston, SC

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Disparities, quality of life, socioeconomic factors, Systemic lupus erythematosus (SLE)

Session Information

Date: Saturday, November 16, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with the potential to severely diminish patients’ quality of life (QoL). SLE disproportionately affects young Black females in both prevalence and disease severity. One goal of this study was to measure the impact of race and other demographic features on mental and physical QoL domains in patients with SLE compared to controls.

Methods: This study was nested in a longitudinal IRB-approved observational registry of patients with SLE and population-matched unaffected controls. We included adults ≥18 years with and without diagnosed SLE who completed at least one 36-Item Short Form version 2 (SF-36) questionnaire. The SF-36 includes 4 physical component score (PCS) domains and 4 mental component score (MCS) domains. Disease damage was measured using the SLICC/ACR Damage Index (SDI). Comparisons were made between demographic factors, disease factors, and SF-36 scores using t-tests for continuous variables, Chi-squared tests for categorical variables, and multivariable logistic regression.

Results: Included were 514 patients with SLE (71.4% identified as Black, 93.2% female) and 215 controls (81.4% Black, 82.3% female). There were no statistically significant differences between patients and controls in high school graduation or insurance status (comparing insured to uninsured), however a greater proportion of controls had private insurance (76.1% vs. 57.3%, p< 0.01). (Table 1)

When comparing QoL scores, patients with SLE had significantly worse scores in all domains compared to controls (all p< 0.01) except mental health (p=0.84). Compared to non-Black patients with SLE, Black patients had significantly worse SF-36 scores in 3 of the 4 PSC domains (physical function, role-physical, bodily pain) and 1 of the 4 MSC domains (role emotional). Although the total PCS was worse in Black patients (38.2±11.2 vs 40.9±12.9, p=0.02), the total MCS was similar between Black and non-Black patients (p=NS). (Table 2)

Black patients with SLE compared to non-Black had higher rates of discoid rash (21.0 vs 13.1, p< 0.01), alopecia (50.3% vs. 27,7%, p< 0.01), arthritis (80.1% vs. 67.2%, p< 0.01), renal disease (56.4% vs. 27.0, p< 0.01), any disease damage (SDI >0) (69.9% vs. 54.7%, p< 0.01), and high disease damage (SDI≥2) (50.4% vs. 31.4%, p< 0.01). MCS and PCS scores were not significantly different in patients with compared to without renal disease. Over 68.8±44.6 months of follow-up, patients with SLE had no significant change in PCS scores but had a significant improvement in MSC scores over time (by 1.6±11.4, p=0.02), predominately among the Black patients (by 1.8±11.9, p=0.02). In a multivariate regression model, there was no significant association between Black race and either total PCS or MCS once adjusted for age, disease duration, sex, insurance status, BMI, SDI damage score, and depression. (Table 3)

Conclusion: In addition to previously reported disparities in health outcomes between Black and non-Black patients with SLE, our study finds substantial differences in self-reported QoL that are likely multifactorial in etiology. The continuation of this work will help inform future interventions to improve QoL for patients with SLE.

Supporting image 1

Table 1. Demographics of controls and patients with SLE

Supporting image 2

Table 2. SF_36 QoL scores compared between cases and controls and further categorized by race

Supporting image 3

Table 3. Clinical characteristics of patients in SLE and associated SF_36 QoL scores


Disclosures: V. Delk: None; D. Wilson: None; G. Gilkeson: None; J. Oates: None; D. Kamen: Alpine Immune Sciences, 1, Bristol Myers Squibb (BMS), 1.

To cite this abstract in AMA style:

Delk V, Wilson D, Gilkeson G, Oates J, Kamen D. Disparities in Health-Related Quality of Life Among Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/disparities-in-health-related-quality-of-life-among-patients-with-systemic-lupus-erythematosus/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disparities-in-health-related-quality-of-life-among-patients-with-systemic-lupus-erythematosus/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology